A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

ISF35

Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.

Trial Locations (1)

University of Texas M.D. Anderson Cancer Center, Houston